OncoMatch/Clinical Trials/NCT06863272
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Is NCT06863272 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for castration-resistant prostatic cancer.
Treatment: Docetaxel · Ifinatamab Deruxtecan · Opevesostat · Abiraterone · Enzalutamide · Rescue Medication — The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen receptor pathway inhibitor
Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
Cannot have received: taxane-based chemotherapy for metastatic castration-resistant prostate cancer
Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA Hematology & Oncology ( Site 0003) · Los Angeles, California
- University of California-Irvine Medical Center ( Site 0016) · Orange, California
- UCSF Medical Center at Mission Bay ( Site 0034) · San Francisco, California
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026) · Washington D.C., District of Columbia
- University of Michigan ( Site 0021) · Ann Arbor, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06863272 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane-based chemotherapy for metastatic castration-resistant prostate cancer disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages